Auperin A, Le PC, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.
Article
CAS
Google Scholar
Pignon JP, Stewart LA. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer. 1996;77(11):2413–4.
Article
CAS
Google Scholar
Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer. 1995;76(4):593–601.
Article
CAS
Google Scholar
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–74.
Article
CAS
Google Scholar
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
Article
CAS
Google Scholar
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91–100.
Article
Google Scholar
Liu Z, Wang F, Chen X. Integrin alpha(v)beta(3)-targeted cancer therapy. Drug Dev Res. 2008;69(6):329–39.
Article
CAS
Google Scholar
Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4(2):123–31.
Article
CAS
Google Scholar
Yu YP, Wang Q, Liu YC, Xie Y. Molecular basis for the targeted binding of RGD-containing peptide to integrin alphaVbeta3. Biomaterials. 2014;35(5):1667–75.
Article
CAS
Google Scholar
Iagaru A, Gambhir SS. Imaging tumor angiogenesis: the road to clinical utility. AJR Am J Roentgenol. 2013;201(2):W183–91.
Article
Google Scholar
Gao S, Wu H, Li W, Zhao S, Teng X, Lu H, et al. A pilot study imaging integrin alphavbeta3 with RGD PET/CT in suspected lung cancer patients. Eur J Nucl Med Mol Imaging. 2015;42(13):2029–37.
Article
CAS
Google Scholar
Wu C, Yue X, Lang L, Kiesewetter DO, Li F, Zhu Z, et al. Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors. Theranostics. 2014;4(5):546–55.
Article
Google Scholar
Liu J, Yuan S, Wang L, Sun X, Hu X, et al. Diagnostic and predictive value of using RGD PET/CT in patients with cancer: a systematic review and meta-analysis. Biomed Res Int. 2019;2019:8534761.
PubMed
PubMed Central
Google Scholar
Tonnelet D, Bohn MP, Becker S, Decazes P, Camus V, et al. Angiogenesis imaging study using interim [(18)F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence. EJNMMI Res. 2021;11(1):37.
Article
CAS
Google Scholar
Liu J, Wu L, Liu Z, Seery S, Li J, Gao Z, et al. (18)F-RGD PET/CT and systemic inflammatory biomarkers predict outcomes of patients with advanced NSCLC receiving combined antiangiogenic treatment. Front Oncol. 2021;11:671912.
Article
Google Scholar
Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54(5):691–8.
Article
CAS
Google Scholar
Nakajima N, Kataoka M, Sugawara Y, Ochi T, Kiyoto S, Ohsumi S, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2013;87(4):738–46.
Article
Google Scholar
Wolf Y, Bartok O, Patkar S, Eli GB, Cohen S, Litchfield K, et al. UVB-induced tumor heterogeneity diminishes immune response in melanoma. Cell. 2019;179(1):219-35.e21.
Article
CAS
Google Scholar
Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of (1)(8)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38(9):1628–35.
Article
CAS
Google Scholar
Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52(5):690–6.
Article
Google Scholar
Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59(4):971–82.
Article
Google Scholar
Askoxylakis V, Dinkel J, Eichinger M, Stieltjes B, Sommer G, Strauss LG, et al. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Radiat Oncol. 2012;7:157.
Article
Google Scholar
Zhai Y, Ma H, Hui Z, Zhao L, Li D, Liang J, et al. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. Radiother Oncol. 2019;131:27–34.
Article
CAS
Google Scholar
Honglian M, Zhouguang H, Fang P, Lujun Z, Dongming L, et al. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: updated follow-up results from two phase II trials. Thorac Cancer. 2020;11(4):898–906.
Article
Google Scholar
Luan X, Huang Y, Gao S, Sun X, Wang S, Ma L, et al. (18)F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2016;43(13):2336–42.
Article
CAS
Google Scholar
Zhang H, Liu N, Gao S, Hu X, Zhao W, Tao R, et al. Can an (1)(8)F-ALF-NOTA-PRGD2 PET/CT scan predict treatment sensitivity to concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma. J Nucl Med. 2016;57(4):524–9.
Article
CAS
Google Scholar
Li L, Ma L, Shang D, Liu Z, Yu Q, Wang S, et al. Pretreatment PET/CT imaging of angiogenesis based on (18)F-RGD tracer uptake may predict antiangiogenic response. Eur J Nucl Med Mol Imaging. 2019;46(4):940–7.
Article
Google Scholar
Greenspan BS. Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging. Transl Lung Cancer Res. 2017;6(6):617–20.
Article
CAS
Google Scholar
Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, et al. Role of various metabolic parameters derived from baseline 18F-FDG PET/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy. Clin Nucl Med. 2018;43(1):e8-8e17.
Article
Google Scholar
Sutic M, Vukic A, Baranasic J, Forsti A, Dzubur F, Samarzija M, et al. Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management. J Pers Med. 2021;11(11):1102.
Article
Google Scholar